anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of traditional Chinese medicines and provides a medicine used for treating seborrheic dermatitis to solve the problem of treating seborrheic dermatitis. The medicine is prepared from white paeony root, hawthorns, immature bitter orange, rhubarb root and rhizome, liquorice, raw atractylodes macrocephala, orange fruit, raw seed of Job's tear, yam rhizome, plantain seed, cortex dictamni, gentian, white mulberry root-bark, Chinese wolfberry root-bark, pagoda tree flower and lightyellow sophora root according to a certain ratio. 700ml of water is added to first dose of the medicines to decoct the medicines until the decoction is 200ml; 500ml of water is added to second dose of the medicines until the decoction is 200ml. The medicine is taken twice a day on an empty stomach, once in the morning and once in the evening. In the traditional Chinese medicine preparation, raw atractylodes macrocephala, orange fruit, raw seed of Job's tear, plantain seed and yam rhizome have the functions of tonifying the spleen and promoting diuresis; white mulberry root-bark, Chinese wolfberry root-bark, pagoda tree flower, cortex dictamni, lightyellow sophora root and gentian have the functions of clearing away heat to relieve itching; white paeony root, hawthorns, immature bitter orange, rhubarb root and rhizome and liquorice have the functions of removing stasis. Through compatible use and synergism of the medicines, the medicine has good treatment effects on seborrheic dermatitis.
The voltage-gated sodium (Nav) channel is a crucial molecular component responsible for initiating and propagating action potentials. While the α subunit, forming the channel pore, plays a central role in this function, the complete physiological function of Nav channels relies on crucial interactions between the α subunit and auxiliary proteins, known as protein-protein interactions (PPI). Nav blocking peptides (NaBPs) have been recognized as a promising and alternative therapeutic agent for pain and itch. Although traditional experimental methods can precisely determine the effect and activity of NaBPs, they remain time-consuming and costly. Hence, machine learning (ML)-based methods that are capable of accurately contributing in silico prediction of NaBPs are highly desirable. In this study, we develop an innovative meta-learning-based NaBP prediction method (MetaNaBP). MetaNaBP generates new feature representations by employing a wide range of sequence-based feature descriptors that cover multiple perspectives, in combination with powerful ML algorithms. Then, these feature representations were optimized to identify informative features using a two-step feature selection method. Finally, the selected informative features were applied to develop the final meta-predictor. To the best of our knowledge, MetaNaBP is the first meta-predictor for NaBP prediction. Experimental results demonstrated that MetaNaBP achieved an accuracy of 0.948 and a Matthews correlation coefficient of 0.898 over the independent test dataset, which were 5.79% and 11.76% higher than the existing method. In addition, the discriminative power of our feature representations surpassed that of conventional feature descriptors over both the training and independent test datasets. We anticipate that MetaNaBP will be exploited for the large-scale prediction and analysis of NaBPs to narrow down the potential NaBPs.
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disorder marked by hepatic fat accumulation and inflammatory infiltrates which may evolve to cirrhosis. Clinical studies have demonstrated the higher risk of MASH development after tamoxifen (TAM) therapy, especially in obese patients. Therefore, we aimed to evaluate MASH induction by TAM combined with high fat diet (HFD) and the potential interference of memantine (MEMA) with MASH progression via modulation of SIRT6 and its related signaling pathways. MASH was induced in female Wistar rats by co-administration of TAM (25 mg/kg/day, p.o.) and HFD for 5 weeks. Liver function biomarkers, tissue triglyceride and cholesterol, MASH scoring, SIRT6 with its related signals, and lipid synthesis/oxidation markers were estimated. By comparison to MASH group, MEMA improved liver function indices (ALT, AST, ALP, albumin) and reduced the progression of MASH, evidenced by decreased accumulation of lipids in hepatic tissue, improved histological features, and reduced MASH scoring. MEMA enhanced hepatic SIRT6 and downregulated p-AKT/mTOR signaling, that subsequently reduced expressions of the lipid synthesis biomarkers (SREBP1c, SCD), while elevating the lipid oxidation markers (PPAR-α, CPT1). Moreover, MEMA enhanced NRF2/HO-1 signaling, with subsequently improved antioxidant defense and pro-inflammatory/anti-inflammatory cytokines balance. Analysis of SIRT6 correlations with p-AKT/mTOR, NRF2/HO-1, SREBP1c, and PPAR-α further confirmed our results. Consequently, we conclude that MEMA could interfere with MASH progression, at least in part, via enhanced SIRT6 expression and modulation of its related p-AKT/mTOR and NRF2/HO-1 signaling pathways, eventually reducing liver steatosis and inflammation. That could be a promising therapeutic modality for curbing MASH progression.
Secure custody transfers of items among entities including secure lockable compartments are disclosed, wherein users may securely transfer custody of items to and from secure lockable compartments. Records of custody transfers and the custody transfers recorded therein may be associated to a chain of custody. A chain of custody may have an originating entity, one or more intermediary entities, which may include secure lockable compartments, and an end recipient entity. Custody transfers to a secure lockable compartment may include a release authority specifying a subsequent custody transfer, wherein a specified receiving user may access the secure lockable compartment using a portable wireless device and/or using a keypad to enter a provided access token. Custody transfer records may be secured using record certificates useable to authenticate data comprised therein. Record certificates may be written to and retrieved from a ledger, which may be a secure ledger such as a blockchain ledger.
The present invention relates to a leukemia-associated virus immunogens, vaccines, and assays. The immunogens are relatively short polypeptides with peptide sequences corresponding to the antigenic determinant domains of a leukemia-associated virus envelope protein. The immunogens when introduced into a host stimulate the production of antibodies which immunoreact with the polypeptides and the leukemia-associated virus. The immunogens may be used together with other components such as adjuvants to form immunizing compositions such as vaccines. The antibodies may be used together with other components in an assay system to detect the presence of a leukemia-associated virus antigen in a body fluid sample. The antibodies can also be used in the treatment of leukemia-associated virus infections.
The system described herein collects patient data passively and non-passively via onboard and external sensors, and combines the data with past clinical history to generate digital biomarkers. The collected data can also be further combined with other data generating systems to more accurately predict disease exacerbations. The system monitors the digital biomarkers in real-time, and can detect a change in the disease state prior to clinical decompensation and suggest pre-emptive intervention. The system enables a patient to be treated early in the clinical timeline when the disease exacerbation is at the subclinical level rather than waiting until the disease exacerbation reaches the clinical level. Acting when the exacerbation is at the subclinical level enables preemptive treatment rather than reactive treatment, which is often more cost effective while improving clinical outcomes. The system is able to make the predictions by detecting subclinical changes in digital biomarkers that are generated from respiratory, cardiac, patient reported symptoms, user behaviors, and environmental triggers.
AIMS: Rare studies have investigated the association between heterogeneity of motor progression and risk of early cognitive impairment in Parkinson's disease (PD). In this study, we aim to identify distinct trajectories of motor progression longitudinally and investigate their impact on predicting mild cognitive impairment (MCI).
METHODS: A 5-year cohort including 415 PD patients at baseline was collected from the Parkinson's Progression Markers Initiative. The severity of motor symptoms was evaluated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III. The latent class trajectory model and nonlinear mixed-effects model were used to analyze and delineate the longitudinal changes in motor symptoms. Propensity score matching (PSM) was used to minimize the impact of potential confounders. Cox proportional hazard models were applied to calculate hazard ratios for MCI, and a Kaplan-Meier curve was generated using the occurrence of MCI during the follow-up as the time-to-event.
RESULTS: Two latent trajectories were identified: a mild and remitting motor symptoms class (Class 1, 33.01%) and a severe and progressive motor symptom class (Class 2, 66.99%). Patients in Class 2 initially exhibited severe motor symptoms that worsened progressively despite receiving anti-PD medications. In comparison, patients in Class 1 exhibited milder symptoms that improved following drug therapy and a slower progression. During a 5-year follow-up, patients in Class 2 showed a higher risk of developing MCI compared to those in Class 1 before PSM (Log-Rank 28.58, p < 0.001) and after PSM (Log-Rank 8.20, p = 0.004).
CONCLUSIONS: PD patients with severe and progressive motor symptoms are more likely to develop MCI than those with mild and stable motor symptoms.
Pregnancy Category C

Methylphenidate has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day, which is approximately 100 times and 40 times the maximum recommended human dose on a mg/kg and mg/m 2basis, respectively. 

A reproduction study in rats revealed no evidence of harm to the fetus at oral doses up to 30 mg/kg/day, approximately 15-fold and 3-fold the maximum recommended human dose of CONCERTA on a mg/kg and mg/m 2basis, respectively. The approximate plasma exposure to methylphenidate plus its main metabolite PPAA in pregnant rats was 1–2 times that seen in trials in volunteers and patients with the maximum recommended dose of CONCERTA based on the AUC. 

The safety of methylphenidate for use during human pregnancy has not been established. There are no adequate and well-controlled studies in pregnant women. CONCERTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
PURPOSE: Periodontitis-associated bacteria, such as Porphyromonas gingivalis and Fusobacterium nucleatum, are closely linked to the risk of oral squamous cell carcinoma (OSCC). Emerging studies have indicated that another common periodontal pathogen, Prevotella intermedia (P. intermedia), is enriched in OSCC and could affect the occurrence and progression of OSCC. Our aim is to determine the effects of P. intermedia on the progression of OSCC and the role of antibiotics in reversing these effects.
METHODS: In this study, a murine xenograft model of OSCC was established, and the mice were injected intratumorally with PBS (control group), P. intermedia (P.i group), or P. intermedia combined with an antibiotic cocktail administration (P.i + ABX group), respectively. The effects of P. intermedia and ABX administration on xenograft tumor growth, invasion, angiogenesis, and metastasis were investigated by tumor volume measurement and histopathological examination. Enzyme-linked immunosorbent assay (ELISA) was used to investigate the changes in serum cytokine levels. Immunohistochemistry (IHC) was adopted to analyze the alterations in the levels of inflammatory cytokines and infiltrated immune cells in OSCC tissues of xenograft tumors. Transcriptome sequencing and analysis were conducted to determine differential expression genes among various groups.
RESULTS: Compared with the control treatment, P. intermedia treatment significantly promoted tumor growth, invasion, angiogenesis, and metastasis, markedly affected the levels of inflammatory cytokines, and markedly altered M2 macrophages and regulatory T cells (Tregs) infiltration in the tumor microenvironment. However, ABX administration clearly abolished these effects of P. intermedia. Transcriptome and immunohistochemical analyses revealed that P. intermedia infection increased the expression of interferon-stimulated gene 15 (ISG15). Correlation analysis indicated that the expression level of ISG15 was positively correlated with the Ki67 expression level, microvessel density, serum concentrations and tissue expression levels of inflammatory cytokines, and quantities of infiltrated M2 macrophages and Tregs. However, it is negatively correlated with the quantities of infiltrated CD4+ and CD8+ T cells.
CONCLUSION: In conclusion, intratumoral P. intermedia infection aggravated OSCC progression, which may be achieved through upregulation of ISG15. This study sheds new light on the possible pathogenic mechanism of intratumoral P. intermedia in OSCC progression, which could be a prospective target for OSCC prevention and treatment.
<P>PROBLEM TO BE SOLVED: To provide a bleaching cosmetic which has a strong skin melamine compound-inhibiting action and does not have problems on safety, such as skin irritation and skin sensitization.  <P>SOLUTION: This bleaching cosmetic is characterized by comprising Oldenlandia diffusa (Wild.) Roxb or its extract, and one or more selected from anti-oxidizing agents, inflammatory agents, polymers, and polyhydric alcohols. A melanine production-inhibiting action caused by a c-kit expression-inhibiting action has been found in the Oldenlandia diffusa (Wild.) Roxb or its extract. This bleaching cosmetic does not cause problems such as skin irritation and skin sensitization, is excellent in a bleaching effect, and has high safety.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE: Provided are a novel lactobacillus sp. strain and its use. The strain is isolated from the fermentative liquid of Kimchi and identified as a novel lactobacillus sp. microorganism, lactobacillus paracasei viro-01. Also, provided are a probiotic composition, a feed composition and a food composition containing it. CONSTITUTION: Lactobacillus paracasei viro-01(KCTC 10132BP) has acid and bile resisting properties and stability in a human body, inhibits the activities of pathogenic bacteria, increases helpful bacteria by changing enteric flora, reduces the occurrence frequency of diarrhea, and decompose odorant. its fermentative liquid is manufactured by the steps of: inoculating Lactobacillus paracasei viro-01(KCTC 10132BP) to fruit juice; anaerobically fermenting it at 15-45 deg.C and fermenting it at 20-40 deg.C until its acidity reaches 2.0-5.0.
The present application discloses a secretory protein, including polypeptide sequence, nucleic acid sequence, operating principle and application area of sDSS1 protein. The sDSS1 protein is a secretory protein of higher primate, and can be detected in human serum and CSF. The sDSS1 protein can be combined with oxidation protein under nonenzymatic condition to form polymer or with Aβ polypeptide to reduce formation of Aβ oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidation protein, Aβ oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly. The protein can be used to prevent and treat the diseases induced by oxidation protein, glycated protein, Aβ protein accumulation, amylin protein accumulation or excessive formation or accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine.
This invention relates to a novel single chain antibody molecules. The starting antibodies from which are derived these molecules are T16 and 48-127. Theses antibodies recognize different epitopes of the gp54 antigen which is expressed at the surface of a plurality of carcinoma cells. Are disclosed: the sequence of the light and heavy chain and of a single chain antibody molecule (scFv) for each antibody. Both scFvs bind gp54-expressing cells, and the immune complexes are internalised by cells. Therapeutic and diagnostic compositions/methods are also disclosed.
The invention discloses an anti-INHBA monoclonal antibody and application thereof, and provides an anti-INHBA monoclonal antibody or an antigen binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR-H1 shown as SEQ ID NO. 1, a CDR-H2 shown as SEQ ID NO. 2, a CDR-H3 shown as SEQ ID NO. 3, and the light chain variable region comprises a CDR-L1 shown as SEQ ID NO. 9, a CDR-L2 shown as SEQ ID NO. 10 and a CDR-L3 shown as SEQ ID NO. 11. The monoclonal antibody provided by the invention can prevent or treat diseases caused by abnormal INHBA protein, and can enhance the curative effect of treating cancers when being used in combination with pyrimidine analogues.
A key but often neglected component of genomic instability is the emergence of single-stranded DNA (ssDNA) gaps during DNA replication in the absence of functional homologous recombination (HR) proteins, such as RAD51 and BRCA1/2. Research in prokaryotes has shed light on the dual role of RAD51's bacterial ortholog, RecA, in HR and the protection of replication forks, emphasizing its essential role in preventing the formation of ssDNA gaps, which is vital for cellular viability. This phenomenon was corroborated in eukaryotic cells deficient in HR, where the formation of ssDNA gaps within newly synthesized DNA and their subsequent processing by the MRE11 nuclease were observed. Without functional HR proteins, cells employ alternative ssDNA gap-filling mechanisms to ensure survival, though this compensatory response can compromise genomic stability. A notable example is the involvement of the translesion synthesis (TLS) polymerase POLζ, along with the repair protein POLθ, in the suppression of replicative ssDNA gaps. Persistent ssDNA gaps may result in replication fork collapse, chromosomal anomalies, and cell death, which contribute to cancer progression and resistance to therapy. Elucidating the processes that avert ssDNA gaps and safeguard replication forks is critical for enhancing cancer treatment approaches by exploiting the vulnerabilities of cancer cells in these pathways.
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE)and second-line therapy with topotecan has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and 2-year survival is less than 10%. There is no standard treatment recommendation for this group of patients who failed to second-line therapy and had good performance status. Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine. And this clinical trial is designed to prospectively investigate the efficacy and safety of apatinib in recurrent SCLC patients in our center.
Perfusion index (PI) is one of the many vital signs monitored to assess the clinical status of a patient. PI is determined from the pulsatile part of the plethysmographic curve, with typical values measured on the fingers ranging from 0.02% to 20%. Although PI is a relatively newly measured parameter, it has already found application in many areas of clinical medicine. It can be used as an indicator of the severity of health status in different groups of critically ill patients, e.g. in patients with sepsis, in patients after cardiac arrest, for early detection of critical heart defects, for indirect assessment of patient pain, as an indicator of fluid therapy and reactivity, or for assessment and evaluation of anaesthesia in the operating room. However, there is currently no standardised calculation of PI and different manufacturers use different algorithms for the calculation. The consequence is that absolute measured values cannot be compared between devices.
Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 2.5% AR100DP1 topical administration is 62.5 mg/day (2.5% × 1,250 × 2 = 62.5).
BACKGROUND: Follicular lymphoma (FL) is a highly treatable, indolent non-Hodgkin lymphoma. Although FL is considered incurable, a patient without progression of disease by 24 months after treatment is predicted to have a survival consistent with persons without lymphoma. Using a sensitive assessment of minimal residual disease (MRD), we tested the hypothesis that MRD monitoring can predict long term remissions.
METHODS: Unselected patients who were in a clinical remission for at least 24 months after their last treatment were enrolled and monitored prospectively for MRD detectability using a sensitive next-generation sequencing assay (clonoSEQ, Adaptive Biotechnologies, Seattle, WA).
RESULTS: Forty-seven consecutive patients were monitored. We evaluated the MRD thresholds 10-4, 10-5, and 10-6 for the ability to predict long-term remissions in this cohort and determined that undetectable disease at 10-6 was the best predictor with a specificity and negative predictive value (NPV) of 70% and 100%, respectively. While 3 patients exhibited clinical disease progression during the course of the study, none of the 31 patients with persistent MRD undetectability at 10-6 experienced relapse.
CONCLUSIONS: A significant proportion (31/47; 66.0%) of FL patients in clinical remission after ≥24 months following last therapy were undetectable at 10-6 by a sensitive assay of MRD. The threshold of sensitivity was 100%, specificity 70%, with a PPV of 19%, but a NPV of 100%. Although longer follow-up is needed for confirmation, many of these patients may continue to have durable complete remissions.
BACKGROUND: Vital signs are an essential component of the emergency department (ED) assessment. Vital sign abnormalities are associated with adverse events in the ED setting and may indicate a risk of poor outcomes after ED discharge.
CLINICAL QUESTION: What is the risk of adverse events among adult patients with abnormal vital signs at the time of ED discharge?
EVIDENCE REVIEW: Studies retrieved included 6 retrospective studies with adult patients discharged from the ED. These studies evaluated adverse outcomes in adult patients discharged from the ED with abnormal vital signs. Hypotension at discharge was associated with the highest odds of adverse events after discharge. Tachycardia was also a key predictor of adverse events after discharge and may be easily missed by ED clinicians.
CONCLUSION: Based on the available evidence, the specific vital sign abnormality and the number of total abnormalities influence the risk of adverse outcomes after discharge. Vital sign abnormalities at the time of discharge also increase the risk of ED revisit. The most common abnormal vital sign at the time of discharge is tachycardia.